Abexinostat (INN,[1] formerly PCI-24781) is an experimental drug candidate for cancer treatment.[2] It is currently underdevelopment by Pharmacyclics and is in Phase II clinical trials for B-cell lymphoma.[3] Pre-clinical study suggests the potential for treatment of different types of cancer as well.[4][5][6][7]
Abexinostat exerts its effect as a histone deacetylase inhibitor.
No comments:
Post a Comment